STUDresearch · Peptide
VIP
Also known as
Vasoactive Intestinal Peptide · Vasoactive Intestinal Polypeptide · Aviptadil (pharmaceutical synthetic VIP) · VIP nasal spray · Intranasal VIP · VIP-CIRS / Shoemaker VIP · Invicorp component (aviptadil + phentolamine ED product — different use/route)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Mixed
Intranasal / SubQ / inhaled / IV
Immune & neuropeptides
Mixed — nasal CIRS use, systemic SubQ discussion, and inhaled or IV pharmaceutical research are distinct contexts.
What people say
VIP is an endogenous 28-amino-acid signaling peptide; synthetic pharmaceutical VIP is called aviptadil. Nasal CIRS use is different from inhaled or IV pulmonary research and from intracavernosal combination products.
Doses people talk about
The rows retain a common nasal unit and study or clinic totals. A four-times-daily frequency is incomplete without per-actuation amount and route.
How it may feel
Nasal reports conflict: some describe early anxiety, bloating, pain or flu-like flares before later better days; others report no clear benefit or severe prolonged worsening. One QID author's six-week update followed the same difficult 3–4-week start.
Common compounded nasal unit~50 mcg per actuation
Commonly discussed for CIRS sprays; delivered dose depends on product calibration and concentration.
Open-label nasal series50 mcg four times daily (~200 mcg/day)
A selected refractory CIRS cohort used nasal aerosol for extended replacement of at least 18 months.
Higher clinic-page variant50 mcg in each nostril four times daily (~400 mcg/day)
A different clinic convention with twice the daily total of a single-spray QID schedule; the phrase “four times daily” alone does not distinguish them.
Half-life & effect duration
- Half-life in the body
- IV studyAbout 1 minute
- Other summariesAbout 1–2 minutes
- Felt duration people report
- Some nasal accountsImmediate worsening; difficult first 3–4 weeks, then better by week 6
- Other accountsImprovement around 1–2 months, no benefit or months-long adverse recovery
Cycles people discuss
CIRS discussions place VIP late in a multi-step protocol and use continuous multi-dose replacement for weeks to months, not a short bodybuilding cycle. The open-label series continued at least 18 months and later reduced frequency for some participants.
Timing
CIRS schedules place VIP late in a prerequisite-heavy protocol and spread nasal doses across waking hours, commonly four times daily in the inspected open-label schedule; some clinic notes use a roughly 15-minute post-spray lab check around the first dose. Inhaled, IV and SubQ research schedules are different contexts, not interchangeable timing advice.
Stacks
CIRS discussions pair environmental remediation, binders and MARCoNS work before or with VIP. Forum peptide stacks may also include immune, nootropic or injury peptides, but those combinations confound the VIP-specific experience.
Watch for
Lipase / pancreatitis watch: Major protocol contraindication talk — rising fasting lipase (with or without abdominal pain) is a stop signal; open-label series noted one transient lipase rise without pain that resolved; some summaries cite roughly ~1% pancreatitis risk class language in consent-style materials.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Average plasma disappearance half-time was one minute after IV VIP in four healthy volunteers.
VIP was infused intravenously at three rates for 30 minutes and measured by radioimmunoassay; the post-infusion decline was first-order.
Four-person 1978 IV study; not intranasal residence, SubQ absorption, intact brain exposure or a felt-duration measurement.
- Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects (opens in a new tab)Abstract: four healthy volunteers, three 30-minute IV infusion rates, radioimmunoassay, first-order decline and average one-minute disappearance half-time after infusion. Actual abstract read.Very small older IV study; does not measure modern compounded nasal or SubQ formulations or subjective duration.
Felt duration people report
Nasal CIRS accounts range from immediate worsening to later better days, no clear change and prolonged adverse recovery.
One QID author's same-account update changed from anxiety, bloating and feeling off at week one to feeling much better at week six after 3–4 difficult weeks; other authors described improvement near one or two months, no benefit or months-long recovery.
Self-selected reports, different concentrations and frequencies, concurrent CIRS care and other medications; reply authors are not combined into one trajectory.
- Vasoactive intestinal peptide (VIP) experience (opens in a new tab)Read OP and replies: OP nasal QID at one week after MARCoNS/CSM work; anxiety, bloating and feeling off. Distinct authors reported three sprays/week with better days around one month, pain before cognitive change near two months, and months-long recovery after a full-concentration start.Multiple authors with different products, concentrations, schedules and concurrent care; reports do not establish prevalence, mechanism or a shared timeline.
- Vasoactive intestinal peptide (VIP) — same-author cross-post update (opens in a new tab)ThinResist572 cross-post and same-author later reply: at about six weeks, feeling much better after feeling bad for the first 3–4 weeks. Matched to the same OP username and regimen context, not to other reply authors.Unverified self-report, concurrent CIRS protocol and no objective measure, product assay or isolated comparison.
What people say
- Clinic survey tone: Surviving Mold / related writeups claim large numbers of CIRS-prescribing physicians report symptom and marker improvements with intranasal VIP — observational, not blinded RCT. forum
- Aromatase / androgen rebalance talk: Some CIRS protocol pages describe VIP courses as helping stabilize aromatase and rebalance androgens; clinics often monitor DHEA/estradiol. forum
- Outside CIRS fatigue / post-viral: Forum and clinic-adjacent anecdotes exist; controlled evidence for those uses is sparse. anecdote
- Confound warning: Almost always after mold remediation, binders (e.g., cholestyramine / Welchol), MARCoNS treatment, and marker work — single-agent credit is weak. forum
- CIRS symptom load (open-label): Refractory CIRS-WDB open-label series (n=20, nasal VIP ≥18 months): symptoms reduced toward control levels with reported quality-of-life gains in all trial patients. trial
- Inflammatory markers (open-label): Same series described correction trajectories for C4a, TGF-β1, VEGF, MMP-9 (and other protocol markers) over months of replacement plus interval labs. trial
- Hormonal / metabolic markers: Open-label writeups also cite movement of estradiol, testosterone (males), and 25-OH vitamin D toward control ranges in that carefully selected cohort — not proof VIP is a hormone therapy. trial
- Treg shift: Flow-cytometry note in the open-label CIRS series: mean CD4+CD25+ Treg cells rose from ~8.9 to ~22.5 — single small cohort, open-label. trial
- Exercise pulmonary pressure: Normalization of pulmonary artery systolic pressure (PASP) response during exercise is repeatedly highlighted in Shoemaker-protocol VIP literature. trial
- Endogenous VIP / MSH: Protocol education: measured VIP (and often MSH) is low in biotoxin illness; nasal replacement is framed as supporting recovery of those regulatory peptides when upstream steps are done. trial
- Grey matter / NeuroQuant: Open-label imaging literature reports restoration of volume in multiple atrophic grey-matter nuclei on NeuroQuant after extended multi-spray daily VIP courses in CIRS patients. trial
- vWF / clotting abnormalities: Protocol literature discusses return of regulation for acquired von Willebrand–type abnormalities and related clotting markers in some CIRS patients on the full sequence including VIP. trial
- Immune frame (preclinical/reviews): VIP modulates innate and adaptive inflammatory tone; broad anti-inflammatory and host-regulation reviews exist outside CIRS. lab
- Nasal vs IV brain delivery (animal): Optimized rat nasal formulations delivered intact VIP into brain compartments; IV administration showed rapid degradation with no intact VIP recovered in brain/blood in that model. animal
- Pulmonary research (separate lane): Inhaled Aviptadil studied in pulmonary arterial hypertension (e.g., multi-inhalation daily microgram totals); IV Aviptadil studied in ARDS/COVID-era critical care — not the same as gray-market nasal CIRS culture. trial
Doses people talk about
- Unit dose (dominant CIRS compound): Compounded nasal sprays most commonly discussed at ~50 mcg per actuation. forum
- Alternating-nostril language: Many protocol sheets say one spray alternating nostrils QID rather than blasting both sides every time — practice varies by clinic. forum
- Each-nostril QID clinic variant: Some clinic pages describe 50 mcg (1 actuation) each nostril, 4×/day → ~400 mcg/day total; this is a higher daily total than the classic single-spray QID trial wording — readers should not assume all “4×/day” pages mean the same mcg. forum
- Secondary-source band: 4–8 sprays/day at 50 mcg/spray ≈ ~200–400 mcg/day is widely repeated on CIRS/peptide summary pages. forum
- Start-low community/clinic ramps: Examples include 50 mcg twice daily for weeks 1–2, then escalate toward multi-spray daily totals as tolerated; Superpower-style consent language uses stepped mcg totals over weeks. forum
- Severe-atrophy upper talk: Some CIRS protocol reviews cite up to ~24 sprays/day divided across the day for severe brain-atrophy cases only with close fasting lipase monitoring — extreme end of clinic discussion, not mainstream start dose. forum
- Concentration note (clinic talk): Compounding strength is often discussed around ~500 mcg/mL for standard sprays; some practitioners describe temporary ultra-dilute “receptor sensitization” solutions far below that — highly non-standardized. forum
- Inflammatory-support compounder ranges (non-Shoemaker pages): Some compounding blogs list ~0.2–0.4 mg/day intranasal divided — overlaps the 200–400 mcg CIRS band when converted. forum
- Uncertainty: Spray calibration, actual delivered mcg, cold-chain integrity, and source purity vary widely between compounding pharmacies and research vendors. forum
- Strive-style step-up chart (compounding page example): Month 1: 1 spray (50 mcg) four times daily alternating nostrils; may increase to 2 sprays (100 mcg) four times daily in month 2 if tolerated — still clinic/compounder guidance language, not RCT dosing. forum
- SubQ (minority / research-chem culture): Vendor and forum charts float ~50–100 mcg start, ~100–200 mcg 1–2×/day common talk, occasional ~200–300 mcg per dose or ~400 mcg/day upper community totals; Reddit-style logs sometimes mention ~100 mcg/day SubQ. This is not the Shoemaker open-label nasal protocol. forum
- SubQ vs nasal debate: Some peptide users claim SubQ is “more efficient”; CIRS protocol culture still centers prescription compounded nasal after prerequisites — routes are not proven equivalent. forum
- Higher NeuroQuant-oriented counts: Grey-matter literature discusses >6 doses/day for multi-week to multi-month courses; secondary clinical summaries mention dense schedules (including talk of up to ~12 sprays/day over shorter ~6-month windows, or even higher spray counts for severe atrophy) with stricter lipase monitoring — not a casual DIY default. trial
- Why multi-daily nasal: Extremely short plasma half-life makes once-weekly “peptide bro” schedules make little pharmacokinetic sense for native VIP. trial
- Inhaled Aviptadil (PAH research, not CIRS stack): Historical PAH work includes patterns like ~200 µg/day in four inhalations or single-dose ~100 µg acute hemodynamic studies — pharmaceutical research context. trial
- IV Aviptadil (critical care): Multi-day weight-based or escalating infusion protocols in ARDS/COVID-era research — hospital setting only; not gray-market self-injection culture. trial
- Framing: Discussed clinic-protocol, open-label trial, compounding-pharmacy, and forum ranges only — not medical advice, not a prescription, not a consumption guide. forum
- Classic open-label CIRS schedule (Shoemaker 2013 series): 50 mcg VIP (Aviptadil source in paper) four times daily via nasal aerosol ≈ ~200 mcg/day total for extended replacement (≥18 months in that series). trial
- Titration down (trial behavior): After ~6 months in the open-label series, patients titrated from four doses/day toward minimum effective use: some stayed 3–4×/day; some 1–2×/day; some only before strenuous activity; some stopped when stable without relapse. trial
- Invicorp ED dose (name collision): Intracavernosal aviptadil 25 mcg + phentolamine 1–2 mg once daily as needed — completely separate product/use from CIRS nasal VIP. trial
How it may feel
- Days 0–1 (protocol first dose): Many Shoemaker-style clinics give the first 50 mcg nasal spray in-office with pre- and ~15-minute post-dose labs (often TGF-β1 and lipase) and watch for acute symptom/lipase shifts. forum
- Days 1–7: Reports range from little beyond nasal sensation to marked worsening. One nasal QID poster described anxiety, bloating and feeling off at one week after completing other CIRS steps; the same author reported at six weeks that the first 3–4 weeks were difficult but they were then feeling much better. Other authors described slower improvement, no clear benefit or months-long recovery after an overly concentrated start. forumanecdote
- Weeks 1–2: Common “start low / check tolerance” window — some protocols begin BID before multi-spray daily totals; communities treat early worsening as exposure or skipped steps, not a reason to blast dose. forum
- Weeks 3–4: Frequent checkpoint for fog, energy, respiratory irritation, and whether upstream clearance (environment + binders + MARCoNS) was actually complete. forum
- Month 1 trial blocks: Some providers use ~4–6 weeks with labs before committing to multi-month replacement. forum
- Months 2–3: Open-label and clinic narratives often place clearer marker/symptom gains here when exposure stays controlled. trial
- Months 6–18+: Classic refractory open-label series used multi-month to ≥18 months of replacement with interval exams and labs — niche, selected cohort. trial
- Grey-matter timelines: Published NeuroQuant-oriented courses often discuss >12 weeks at higher daily spray counts; one commonly cited pattern is ~4 sprays/day over ~18 months; secondary writeups mention denser spray totals over ~6 months. trial
Cycles people discuss
- Order is the protocol (CIRS): VIP is discussed as a late / final-phase tool after exposure control, toxin binders, MARCoNS eradication, and other Shoemaker steps — not a week-one solo “mold peptide.” forum
- Common prerequisites before full-dose VIP (Shoemaker-style lists): Normal/improved VCS; no ongoing exposure (often framed as ERMI <2 or HERTSMI-2 ≤10); MARCoNS-negative nasal culture; normal serum lipase; preceding lab abnormalities reviewed. forum
- Why not early: Clinics argue high complement (e.g., very high C4a) and residual MARCoNS hemolysins degrade or blunt exogenous VIP / block MSH recovery — “starting VIP too early” is a major community caution. forum
- 4–6 week trial then decide: Some providers reassess labs/symptoms before multi-month commitment. forum
- Re-exposure events: Community pattern is restart or temporarily increase after water-damage re-exposure, then re-stabilize environment first when possible. forum
- Style: Continuous daily multi-dose replacement dominates CIRS talk; short on/off bodybuilding cycles are uncommon and poorly matched to half-life and protocol logic. forum
- Shelf-life as practical cycle: Refrigerated compounded spray often discussed as ~30–60 days usable life — refill logistics shape real-world “blocks.” forum
- Duration (open-label anchor): Refractory series used continuous multi-month replacement for at least 18 months with scheduled follow-up — not a classic 2–4 week bodybuilding-style cycle. trial
- Grey-matter courses: Imaging-oriented writeups emphasize >12 weeks (often much longer) and sometimes higher daily spray counts. trial
- Titrate-down maintenance: After improvement, drop to lowest effective spray frequency rather than indefinite maximum multi-spray load. trial
Timing
- High-inflammation degradation story: Clinic education: administering VIP while C4a is still extremely elevated can result in near-immediate degradation before useful VPAC signaling — one reason prerequisites and upstream steps are emphasized. forum
- Downstream timing mismatch: Clinics separate minute-scale plasma disappearance from weeks-to-months symptom, lab, and NeuroQuant changes. forum
- Spray timing culture: Protocol sheets often spread doses across waking hours (e.g., roughly QID morning-to-evening); some add “inhale with spray” language for pulmonary deposition interest — not RCT-optimized PK. forum
- First-dose lab window: ~15-minute post-spray TGF-β1/lipase checks are a clinic safety/response ritual, not a full PK curve. forum
- Plasma half-life: Native VIP / Aviptadil plasma half-life is about 1–2 minutes (often cited <1–2 min) after IV exposure — among the shortest peptide half-lives discussed in forums. trial
- Elimination note (Aviptadil monographs): After labeled IV work, radioactivity clears largely renally (~35% within 4 h, ~90% within 24 h in cited summaries) — distinct from the minute-scale intact-peptide half-life. trial
- Dosing logic: Fast blood breakdown drives split multi-daily nasal (or research multi-daily SubQ talk), not weekly inject culture. trial
- Intranasal PK (animal): Rat nasal-delivery work recovered intact VIP in brain with optimized pH/excipient formulations; absolute brain fraction of dose was small (~0.1% class of radiolabel in one study) but intact peptide was present — IV controls showed complete degradation. animal
- Volume of distribution talk (Aviptadil): Apparent Vd figures around ~14 mL/kg appear in critical-care summaries — pharmaceutical context. trial
More on what it is
- Why people search it: Almost entirely CIRS / mold-illness / Shoemaker-protocol culture — low measured VIP as a late biotoxin marker, nasal VIP as a late “replacement” step after environment + binders + MARCoNS work. forum
- Mechanism talk (forums + reviews): Anti-inflammatory / immune-calming tone, Treg and cytokine rebalancing, vessel tone (including pulmonary), and neuroendocrine cross-talk often paired with MSH. forum
- What it is: Endogenous 28–amino-acid neuropeptide in the glucagon/secretin family; made in gut, CNS/PNS neurons, immune cells, and lung. Pharmaceutical synthetic form is often called Aviptadil. trial
- Sequence / ID talk: Classic human sequence HSDAVFTDNYTRLRKQMAVKKYLNSILN (28 aa); highly conserved across many mammals. trial
- Receptors: Acts primarily via VPAC1 and VPAC2 GPCRs (shared high-affinity recognition with PACAP family context in reviews). trial
- Evidence honesty: Best-cited human CIRS use is small open-label refractory series + related NeuroQuant / clinic literature — not large multi-center RCTs for DIY mold recovery. Pulmonary Aviptadil work is a different clinical context. trial
- Not this: Not a BPC-157-class soft-tissue healing peptide, not a GH secretagogue, not an FDA-approved consumer mold or “brain regrowth” drug, not interchangeable with Melanotan / full α-MSH just because MSH is co-discussed. trial
- Name collision: “VIP” in ED is usually Invicorp (aviptadil 25 mcg + phentolamine intracavernosal) — same peptide family, completely different indication, dose, and route from CIRS nasal replacement. trial
Stacks
- CIRS sequence stack (non-drug + drug): Remediating water damage + HEPA/air quality + cholestyramine or Welchol-type binders before/with VIP — environment is treated as the real base stack. forum
- MARCoNS clearance first: EDTA/BEG-style nasal regimens to eradicate MARCoNS, then re-culture negative, then VIP — co-administration while MARCoNS-positive is discouraged in protocol culture. forum
- Lab-marker “stack”: Interval monitoring of C4a, TGF-β1, MMP-9, VEGF, VIP, MSH, lipase, and sometimes hormones is part of how clinics judge the course. forum
- Immune peptides (confounded multi-agent): Forums sometimes place VIP near Thymosin Alpha-1, LL-37, or KPV in broader “immune season / biotoxin” kits — attribution to VIP alone is weak. forum
- Nootropic adjacency: Occasional Semax/Selank or other nasal-neuro stacks in biohack threads; evidence for synergy is anecdotal. anecdote
- Healing-peptide adjacency: BPC-157 / TB-500 / GHK-Cu sometimes run in the same recovery season for injury/inflammation goals — different jobs, heavy confound. forum
- Avoid conceptual mashup: VIP nasal replacement ≠ Invicorp ED injection ≠ IV Aviptadil ARDS protocol — do not “stack” those dosing cultures. forum
- MSH co-tracking: Low VIP and low MSH are often co-flagged; VIP is discussed as helping MSH recovery when hemolysin/MARCoNS pressure is gone — not the same as dosing Melanotan. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Nasal local: Irritation, drip, mild burn, congestion, rhinitis-like discomfort from repeated sprays. forum
- Vasoactive sensations: Flushing, warmth, lightheadedness, BP-related “head rush” feelings — expected from a vasodilatory peptide name/history. forum
- Still-exposed flare: Starting VIP while living/working in a water-damaged building is widely reported to worsen symptoms or waste the course. forum
- MARCoNS-positive start: Protocol culture treats persistent MARCoNS as a reason VIP underperforms and MSH stays suppressed. forum
- First-dose monitoring: In-office first spray with pre/post lipase (and symptom watch) is the cautious clinic pattern. forum
- Repeat lipase checks: Common advice: recheck after first use, ~2 weeks in, and after every major spray-count increase. forum
- Mood: Small risk of depression or mood shift is mentioned in some patient-information / inquiry submissions — not a large RCT signal database. forum
- Compounding / cold-chain risk: Wrong concentration, degraded peptide, or unrefrigerated product are practical hazards and false “non-responders.” forum
- Access confusion: Clinic-compounded prescription VIP ≠ anonymous research-chem nasal labeled “not for human use.” forum
- Evidence gap: “Well tolerated” in small open-label selected CIRS cohorts is not long-term DIY safety data across MCAS, psychiatric, infectious, or highly inflamed populations. forum
- Not risk-free replacement: Even protocol advocates frame VIP as conditional on upstream work — not a harmless daily biohack spray. forum
- Lipase / pancreatitis watch: Major protocol contraindication talk — rising fasting lipase (with or without abdominal pain) is a stop signal; open-label series noted one transient lipase rise without pain that resolved; some summaries cite roughly ~1% pancreatitis risk class language in consent-style materials. trial
- Systemic footprint: Multi-system peptide (gut, vessels, immune, lung, brain pathways) → adverse-effect potential if exposure is high or selection is poor. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.